The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2019

Filed:

Sep. 07, 2015
Applicant:

Lutana Gmbh, Stuttgart, DE;

Inventors:

Michaela Arndt, Mannheim, DE;

Jürgen Krauss, Mannheim, DE;

Stefan Kiesgen, Orsfeld, DE;

Assignee:

Lutana GMBH, Stuttgart, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/00 (2006.01); C07K 16/28 (2006.01); C07K 14/08 (2006.01); C07K 16/30 (2006.01); A61K 38/46 (2006.01); C07K 7/08 (2006.01); C12N 7/00 (2006.01); C12N 9/22 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 38/465 (2013.01); A61K 47/65 (2017.08); A61K 47/6889 (2017.08); C07K 7/08 (2013.01); C07K 14/08 (2013.01); C07K 16/30 (2013.01); C12N 7/00 (2013.01); C12N 9/22 (2013.01); C12Y 301/27 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/10 (2013.01); C07K 2319/21 (2013.01); C07K 2319/33 (2013.01); C07K 2319/41 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24132 (2013.01); Y02A 50/386 (2018.01);
Abstract

Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1. Further, described is the use of one or more fusogenic sequence(s) derived from dengue virus glycoprotein E for use in delivery of a therapeutic moiety, a detectable moiety, a nucleic acid molecule, preferably an siRNA, a carrier molecule, preferably a nanoparticle, a liposome and a viral vector into the cytoplasm of a cell.


Find Patent Forward Citations

Loading…